EPISODE · Jun 16, 2026 · 6 MIN
Differential Transthyretin Stabilization in Patients With Wild-Type and Variant Transthyretin Amyloidosis | JACC: CardioOncology
This podcast by Dr. Ron Witteles reviews new data on transthyretin amyloid cardiomyopathy (ATTR‑CM), highlighting differences in transthyretin stabilization between acoramidis and tafamidis across wild-type and variant disease. The discussion underscores the clinical importance of TTR stabilization, emerging biomarkers such as serum transthyretin, and the expanding therapeutic landscape in cardiac amyloidosis.
Embed this episode
NOW PLAYING
Differential Transthyretin Stabilization in Patients With Wild-Type and Variant Transthyretin Amyloidosis | JACC: CardioOncology
No transcript for this episode yet
Similar Episodes
No similar episodes found.